National and Kapodistrian University of Athens
Νευροαπεικονιστικοί παράμετροι και έκβαση ασθενών με ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο σε έδαφος απόφραξης μεγάλου ενδοκράνιου αγγείου που υποβάλλονται σε θεραπείες επαναιμάτωσης
Abstract
dc:descriptionBackground: Advanced neuroimaging (AN) incorporates the knowledge gained from basic research on the pathophysiology of acute ischemic stroke (AIS) over the past decades. The technological evolution and the optimization of the parameters of perfusion imaging offer one of the most important tools that we have to our disposal in the effort to overcome the time limitations and expand the use of reperfusion therapies in the acute phase of IS. In this PhD thesis, we assessed whether and how the prior use of AN and more specifically the use of CTP/MRP with post-processing of the raw data with the RAPID software, regardless of the time passed since the onset of symptoms, increased the application of reperfusion therapies and influenced the outcomes of patients with AIS who received these treatments. At the same time, we evaluated the potential impact of new thrombolytic agents on patients’ outcomes.Methodology1. Potential eligibility for IVT in the extended time window was evaluated by using inclusion criteria from the EXTEND trial. All patients underwent baseline emergent neurovascular imaging using either computed tomography angiography/ computed tomography perfusion (CTA/CTP) or magnetic resonance angiography/magnetic resonance perfusion (MRA/MRP). Images were post processed by the automated software RAPID. 2. We retrospectively evaluated consecutive AIS patients during a six-year period. The study population was divided into two groups according to the neuroimaging protocol used prior to intravenous thrombolysis (IVT) administration (AN+ Vs AN-). Safety outcomes included any intracranial hemorrhage and 3-month mortality. Effectiveness outcomes included door-to-needle time, neurological status on discharge, and functional status at three months assessed by the modified Rankin Scale (mRS). 3. In the second part of this PhD thesis, we prospectively evaluated patients with AIS due to large vessel occlusion (LVO), treated with IVT with or without mechanical thrombectomy in two tertiary stroke centers. Patients were divided into two groups according to the thrombolytic agent used: the first group was treated with standard-dose alteplase (0.9 mg/kg) and the second with 0.25 mg/kg of tenecteplase. Safety outcomes included prevalence of symptomatic intracranial hemorrhage (sICH) and mortality. Efficacy outcomes included averted thrombectomy, major neurological improvement at 24 h (defined as decrease in baseline NIHSS score of 8 points or greater) and functional status on discharge and on 3 months assessed by modified Rankin Scale (mRS). 4. Finally, we assessed all potential eligible studies identified by searching MEDLINE and Scopus databases in order to evaluate the available evidence on the safety and efficacy of intravenous tenecteplase compared with intravenous alteplase provided by nonrandomized studies. Estimates using random-effects models were pooled. Results: In the context of the descriptive analysis, we discovered that 9.8% of patients with IS acutely present within the time window of 4.5–9 hours, and of these, roughly one in three patients (3.2% overall) may undergo reperfusion treatments either with IVT in the so-called extended window based on the criteria of the EXTEND study or with mechanical thrombectomy (MT) based on the criteria of the DEFUSE-3 study. We then extended our observation to a time period of six years before and after the incorporation of AN in our AIS imaging protocol, finding that the use of AN resulted in an increase in the number of patients undergoing reperfusion treatments by approximately 50%. Although the onset-to-treatment time was longer in the AN+ cohort, the two groups did not differ in door-to-needle time, discharge NIHSS-score, symptomatic ICH, any ICH, 3-month favorable functional outcome (mRS-scores of 0–1), 3-month functional independence (mRS-scores of 0–2), distribution of 3-month mRS-scores, or 3-month mortality. In the study comparing tenecteplase to alteplase, nineteen AIS patients with LVO received tenecteplase and 39 received alteplase. We observed a non-significant higher rate of averted thrombectomies (32% versus 18%, p = 0.243) and a non-significant higher rate of sICH (16% versus 5%, p = 0.201) in the tenecteplase group. The rate of 24 h major neurological improvement was higher in the tenecteplase group (64% versus 33%, p = 0.046) but this was marginally attenuated in multivariable analyses (adjusted OR 10.22, 95% CI: 0.73–142.98; p = 0.084). Discharge mRS, 3-months mRS, and 3-month functional independence (mRS scores of 0–2) did not differ (p > 0.2) between the two groups. The rates of 3-month mortality (11% versus 18%, p = 0.703) were similar in the two groups. No independent association between thrombolytic agent and safety or efficacy outcomes emerged in the multivariable logistic regression analyses. Combining the results of this study with five other studies, we performed a meta-analysis including a total of 1820 patients (618 [34%] treated with tenecteplase). We observed that patients receiving tenecteplase had higher odds of 3-month good functional outcome (crude odds ratio [OR], 1.22; 95% CI, 0.90-1.66; adjusted OR, 1.60, 95% CI, 1.08-2.37), successful recanalization (crude OR, 2.82; 95% CI, 1.12-7.10; adjusted OR, 2.38; 95% CI, 1.18-4.81), and early neurological improvement (crude OR, 4.88; 95% CI, 2.03-11.71; adjusted OR, 7.60; 95% CI, 1.97-29.41). No significant differences were detected in 3-month excellent functional outcome proportions (mRS score 0-1; crude OR, 1.53; 95% CI, 0.81-2.91; adjusted OR, 2.51; 95% CI, 0.66- 9.49), symptomatic intracranial hemorrhage (crude OR, 0.97; 95% CI, 0.44-2.16; adjusted OR, 1.16; 95% CI, 0.13-10.50), or parenchymal hematoma (crude OR, 1.20; 95% CI, 0.24-5.95). Conclusions In conclusion, the use of AN in unselected patients with AIS who are potential candidates for reperfusion therapies, increases the delivery yield of these treatments without delaying door-to-needle times or raising questions about their safety or efficacy. Regarding the choice of the optimal thrombolytic agent, our findings provide indications that intravenous tenecteplase may be an alternative treatment option for patients with AIS as it is associated with more favorable clinical outcomes and equal safety compared to intravenous alteplase. However, this hypothesis will be further evaluated in the ongoing large randomized studies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Psychogios, Klearchos
- Ψυχογιός, Κλέαρχος
Subjects
dc:subject × 16- Οξύ ισχαιμικό αγγειακό εγκεφαλικό επεισόδιο
- Ενδοφλέβια θρομβόλυση
- Μηχανική θρομβεκτομή
- Νευροαπεικόνιση
- Διάγνωση /πρόγνωση
- Acute ischemic stroke
- Intravenous thrombolysis
- Mechanical thrombectomy
- Neuroimaging
- Diagnosis /prognosis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Κλινική νευρολογία
- Clinical Medicine
- Medical and Health Sciences
- Clinical Neurology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54575